Retatrutide: difference between revisions
Diff·revision 17 → 18·04:47, 26 Jan 2025
Difference between revision 17 and revision 18 of Retatrutide. 9 lines changed; the page grew by 1,103 bytes.
| Revision 17 — 03:34, 4 Jan 2025 ForgeryFinder (talk) sentence case in headings per PP:MOS 4,597 bytes ±0 | Revision 18 — 04:47, 26 Jan 2025 LiraLotte (talk) label the animal data as animal data in the sentence, not only in the section heading 5,700 bytes +1,103 | ||
|---|---|---|---|
| 17 | }} | 17 | }} |
| 18 | {{hatnote|Retatrutide is investigational and is not approved for use in any indication. For the two-receptor case, see [[Tirzepatide]].}} | 18 | {{hatnote|Retatrutide is investigational and is not approved for use in any indication. For the two-receptor case, see [[Tirzepatide]].}} |
| + | 19 | {{medical|talk=Investigational status}} | |
| + | 20 | {{update|talk=Phase 3 readouts}} | |
| 19 | 21 | ||
| 20 | '''Retatrutide''' (development code '''LY3437943''') is an investigational 39-residue peptide that agonises three class B receptors: the receptor for [[Glucose-dependent insulinotropic polypeptide]], the [[GLP-1 receptor]], and the [[Glucagon|glucagon]] receptor. It is not approved for use in any indication and is under phase 3 evaluation.{{r|coskun2022}} | 22 | '''Retatrutide''' (development code '''LY3437943''') is an investigational 39-residue peptide that agonises three class B receptors: the receptor for [[Glucose-dependent insulinotropic polypeptide]], the [[GLP-1 receptor]], and the [[Glucagon|glucagon]] receptor. It is not approved for use in any indication and is under phase 3 evaluation.{{r|coskun2022}} |
| ⋮ | ⋮ | ||
| 43 | 45 | ||
| 44 | The weight-change curve had not clearly plateaued by 48 weeks at the higher doses, which is unusual in this field and is one reason the phase 3 programme extends further.{{r|jastreboff2023}} A separate phase 2 trial in type 2 diabetes reported glycated-haemoglobin reductions of up to about 2.0 percentage points. | 46 | The weight-change curve had not clearly plateaued by 48 weeks at the higher doses, which is unusual in this field and is one reason the phase 3 programme extends further.{{r|jastreboff2023}} A separate phase 2 trial in type 2 diabetes reported glycated-haemoglobin reductions of up to about 2.0 percentage points. |
| + | 47 | ||
| + | 48 | These are phase 2 results in selected populations and are not a basis for comparison with approved agents. A phase 2 programme is powered for dose selection rather than for outcome estimation, and the confidence intervals around the larger figures are correspondingly wide.{{r|coskun2022}} | |
| + | 49 | ||
| + | 50 | == Safety signals reported to date == | |
| + | 51 | Gastrointestinal events dominated and were dose-related, as expected for the class. Reported nausea rates at the higher doses exceeded those seen with dual agonists, consistent with the larger overall exposure.{{r|jastreboff2023}} | |
| + | 52 | ||
| + | 53 | Two findings are specific to the glucagon component. A dose-dependent increase in heart rate was reported, larger than the two-to-four beats per minute typical of GLP-1 monotherapy and peaking during escalation before partially receding. Transient rises in fasting glucose were observed at the lowest dose in participants with diabetes, consistent with glucagon agonism outrunning GLP-1 agonism when the total dose is low — the predicted failure mode of the design. | |
| 45 | 54 | ||
| 46 | == References == | 55 | == References == |